The leading Australian employee services and platform provider leverages Roche’s innovative rapid antigen test digital tools and scientific solutions to rapidly deploy over 80,000 tests in a month.
13 OCTOBER 2021 Sydney, Australia
Direct Health Solutions (DHS), Australia’s leading employee wellbeing services and platform provider has announced a collaboration with global healthcare company Roche Diagnostics Australia to rapidly scale rapid antigen testing via an innovative, digital-first testing solution.
In Australia, up until now, COVID-19 testing has involved taking a nasal-pharyngeal sample from a person and sending it to a laboratory to be analysed using highly-accurate PCR technology. However, businesses are now turning to rapid antigen testing as a primary COVID-19 surveillance tool and as a key safety approach to encourage employees to return to the workplace.
Rapid antigen testing is fast becoming a key tool to protect workers, and to alleviate concern many employees may have about health risks relating to returning to work when lockdown ends, says Paul Dundon, CEO and Founder of DHS.
“In the past three weeks alone, we have deployed a team of 200 nurses and onsite testers across NSW, Victoria and Queensland, and administered over 80,000 tests on client sites,” Dundon says.
The DHS team provides the SARS-CoV-2 Rapid Antigen Nasal test, supplied by Roche Diagnostics, and administers onsite testing using an easy to use app, NAVIFY® Pass, to track results and administer results.
NAVIFY® Pass allows for multiple tests and a range of data to be managed seamlessly, creating an efficient workflow for the business. It also gives the test recipient their results on their own phone for personal record, or to use to access work sites as necessary. DHS also manages each site’s full test records for any customer or public health reporting requirements.
The DHS health testing team also seamlessly use NAVIFY® Pass to:
- Log into the site profile by scanning a site-specific QR code;
- Scan a test recipient QR from their mobile;
- Take the sample and scan a QR on the test device;
- Enter the result in the NAVIFY® Professional app;
- Send the result straight to the test recipient’s mobile phone, and to a back-end file so DHS can securely and efficiently manage each site.
The DHS collaboration with Roche brings new digital tools and scientific innovation to help improve testing efficiency while helping protect employees and ensuring business continuity.
“Given the highly contagious COVID Delta strain currently in circulation, the faster the infected individual is isolated, the more chance we have to reduce transmission. This is why rapid antigen tests are a great option where speed is key. DHS sees this as critical to future-proof the Australian businesses, protecting workforces and reducing the chance of further lockdowns,” Dundon adds.
Dundon emphasises businesses should not see rapid antigen home testing, set to be available from November, as a replacement for businesses doing their part to protect their staff.
“RAT is going to become even more important for businesses, because with restrictions easing there’s going to be an increase in COVD in the community - that’s where the power of RAT comes into its own. You need to identify the asymptomatic cases while they’re infectious so you prevent them from getting onto the worksite,” says Dundon.
“RAT is here to stay. Even if Government restrictions ease, businesses have a duty of care to ensure the safety and wellbeing of their teams. The UK is an excellent example of how rapid antigen testing on worksites has become an essential part of day-to-day business operations, and it’s making a significant difference in helping balance public health measures with keeping the economy going,” adds Dundon.
“We have delivered approximately 30 million COVID-19 tests in the public health response, and we’re proud to be keeping Australians safe. While normal life returns for residents of NSW - one-third of Australia’s population, we need to continue to be vigilant, as we see high case numbers in Victoria. This is a marathon, not a sprint. Scientific innovation such as RAT is an addition to the testing arsenal to help enable effective management of this pandemic, and will continue to play a leading role,” says Allison Rossiter, Managing Director of Roche Diagnostics Australia.
For more information on rapid antigen testing and the DHS’ RAT services click here.
This announcement was featured in ITBrief Australia, ITBrief NZ, ITBrief Asia, ITWire, Istart Australia, Istart New Zealand and TecHRSeries
About Direct Health Solutions
Direct Health Solutions (DHS) is Australia’s largest 24x7 telehealth provider for employers, offering a range of medical, COVID-19 and RAT services, and specialist HR and safety software platforms.
DHS provides expertise across absence management, injury management, health and safety management, medical services, and employee relations case management.
DHS telehealth services are underpinned by a team of tele-nurses, tele-doctors, tele-physios and tele-psychs, and powered by specialist technology modules.
To date, DHS has supported hundreds of organisations across major industry verticals including energy, retail, telecommunications and transport, and handled millions of calls related to illness, incidents and injuries, globally.
DHS’ vision is to transform businesses and the working lives of all Australians.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche’s diagnostics division in Australia employs over 200 people and has a broad range of in vitro diagnostics. It concentrates on leveraging advanced scientific knowledge and technological progress to increase the medical value of this offering. Roche Diagnostics serves customers spanning the entire healthcare spectrum - from research institutions, hospitals and commercial laboratories to physicians and patients.
For more information, please visit: